Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Research

Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis

Authors: Maoquan Yang, Mingwei Zhang, Qiong Wang, Xiaojing Guo, Peizhen Geng, Jinhua Gu, Wansheng Ji, Li Zhang

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Numerous studies have demonstrated long noncoding RNA (lncRNA) play an important role in the occurrence and progression of cancer, and single nucleotide polymorphisms (SNPs) located in lncRNA are considered to affect cancer suspensibility. Herein, a meta-analysis was carried out to better assess the relationship of H19 polymorphisms and cancer susceptibility.

Methods

A literature search was conducted through using PubMed, EMBASE, and Web of Science databases to obtain relevant publications before Aug 23, 2022. The reference lists of the retrieved studies were also investigated to identify additional relevant articles. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to appraise the risk of various cancers.

Results

There appeared to be a remarkable correlation between the rs2107425 variation and decreased cancer risk among Caucasians. Nevertheless, the rs217727 polymorphism was significantly associated with an increased risk of lung cancer, hepatocellular carcinoma and oral squamous cell carcinoma. Also, we found a significant correlation between the rs2839698 polymorphism and increased cancer risk among Asians, gastric cancer, hepatocellular carcinoma, hospital-based control and larger simple size subgroups, respectively. Similarly, the rs3741219 mutation was notably related to cancer risk in higher quality score. As for rs3024270 polymorphism, the homozygous model was markedly linked to cancer risk in overall analysis and population-based controls. There was no significant association between the rs3741216 polymorphism and cancer risk.

Conclusion

H19 rs2839698 and rs3024270 were closely associated with overall cancer risk. H19 rs2107425 was related to lower cancer risk among Caucasians, while the rs2839698 was related to increased cancer risk among Asians. Our results supported that H19 SNPs were significantly correlated with cancer risk.

Available only for authorised users

Wild CP. The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer. 2019;19(3):123–4.PubMedCrossRef

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022, 72(1).

Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54.PubMedCrossRef

Rossi M, Jahanzaib Anwar M, Usman A, Keshavarzian A, Bishehsari F. Colorectal Cancer and alcohol consumption-populations to molecules. Cancers (Basel) 2018, 10(2).

Yan H, Ying Y, Xie H, Li J, Wang X, He L, Jin K, Tang J, Xu X, Zheng X. Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis. Cancer Manag Res. 2018;10:3781–91.PubMedPubMedCentralCrossRef

Arshad R, Kiani MH, Rahdar A, Sargazi S, Barani M, Shojaei S, Bilal M, Kumar D, Pandey S. Nano-Based theranostic platforms for breast Cancer: a review of latest advancements. Bioeng (Basel) 2022, 9(7).

Sargazi S, Er S, Mobashar A, Gelen SS, Rahdar A, Ebrahimi N, Hosseinikhah SM, Bilal M, Kyzas GZ. Aptamer-conjugated carbon-based nanomaterials for cancer and bacteria theranostics: a review. Chem Biol Interact. 2022;361:109964.PubMedCrossRef

Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Díez-Pascual AM. Breast cancer vaccines: new insights into immunomodulatory and nano-therapeutic approaches. J Control Release. 2022;349:844–75.PubMedCrossRef

Janssen EM, Dy SM, Meara AS, Kneuertz PJ, Presley CJ, Bridges JFP. Analysis of patient preferences in Lung Cancer - estimating acceptable tradeoffs between Treatment Benefit and Side Effects. Patient Prefer Adherence. 2020;14:927–37.PubMedPubMedCentralCrossRef

10.

Chen J, Jiang Y, Zhou J, Liu S, Qin N, Du J, Jin G, Hu Z, Ma H, Shen H, et al. Evaluation of CpG-SNPs in miRNA promoters and risk of breast cancer. Gene. 2018;651:1–8.PubMedCrossRef

11.

Zucman-Rossi J, Villanueva A, Nault J-C, Llovet JM. Genetic Landscape and biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015, 149(5).

12.

Harati-Sadegh M, Sargazi S, Saravani M, Sheervalilou R, Mirinejad S, Saravani R. Relationship between miR-143/145 cluster variations and cancer risk: proof from a Meta-analysis. Nucleosides Nucleotides Nucleic Acids. 2021;40(5):578–91.PubMedCrossRef

13.

Sargazi S, Abghari AZ, Sarani H, Sheervalilou R, Mirinejad S, Saravani R, Eskandari E. Relationship between CASP9 and CASP10 gene polymorphisms and Cancer susceptibility: evidence from an updated Meta-analysis. Appl Biochem Biotechnol. 2021;193(12):4172–96.PubMedCrossRef

14.

Harati-Sadegh M, Mohammadoo-Khorasani M, Sargazi S, Saravani R, Shahraki S, Eskandari E. Quantitative Assessment of the Effects of IL-1ß -511 C > T variant on breast Cancer risk: an updated Meta-analysis of 3331 cases and 3609 controls. Lab Med. 2021;52(1):36–46.PubMedCrossRef

15.

Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol 2009, 578.

16.

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.PubMedCrossRef

17.

Jalali S, Singh A, Maiti S, Scaria V. Genome-wide computational analysis of potential long noncoding RNA mediated DNA:DNA:RNA triplexes in the human genome. J Transl Med. 2017;15(1):186.PubMedPubMedCentralCrossRef

18.

Chen L, Zhang S. Long noncoding RNAs in cell differentiation and pluripotency. Cell Tissue Res. 2016;366(3):509–21.PubMedCrossRef

19.

Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014, 15(1).

20.

Tran N-T, Su H, Khodadadi-Jamayran A, Lin S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC, et al. The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation. EMBO Rep. 2016;17(6):887–900.PubMedPubMedCentralCrossRef

21.

Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 2014;9(9):1932–56.PubMedCrossRef

22.

Taniue K, Akimitsu N. The functions and unique features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci 2021, 22(2).

23.

Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–504.PubMedPubMedCentralCrossRef

24.

Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(11):1097–109.PubMedCrossRef

25.

Zou Y, Jiang Z, Yu X, Sun M, Zhang Y, Zuo Q, Zhou J, Yang N, Han P, Ge Z, et al. Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS ONE. 2013;8(11):e79598.PubMedPubMedCentralCrossRef

26.

Shen Y, Xia E, Bhandari A, Wang X, Guo G. LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in papillary thyroid carcinoma. Biosci Rep 2018, 38(5).

27.

Ou L, Wang D, Zhang H, Yu Q, Hua F. Decreased expression of mir-138-5p by lncRNA H19 in Cervical Cancer promotes Tumor Proliferation. Oncol Res. 2018;26(3):401–10.PubMedPubMedCentralCrossRef

28.

Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012;279(17):3159–65.PubMedCrossRef

29.

Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells 2019, 8(9).

30.

Ghahramani Almanghadim H, Ghorbian S, Khademi NS, Soleymani Sadrabadi M, Jarrahi E, Nourollahzadeh Z, Dastani M, Shirvaliloo M, Sheervalilou R, Sargazi S. New Insights into the importance of long non-coding RNAs in Lung Cancer: future clinical approaches. DNA Cell Biol. 2021;40(12):1476–94.PubMedCrossRef

31.

Pachnis V, Brannan CI, Tilghman SM. The structure and expression of a novel gene activated in early mouse embryogenesis. EMBO J. 1988;7(3):673–81.PubMedPubMedCentralCrossRef

32.

Kallen AN, Zhou X-B, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi J-S, Zhang H, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101–12.PubMedCrossRef

33.

Koukoura O, Sifakis S, Zaravinos A, Apostolidou S, Jones A, Hajiioannou J, Widschwendter M, Spandidos DA. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta. 2011;32(1):51–7.PubMedCrossRef

34.

Mutter GL, Stewart CL, Chaponot ML, Pomponio RJ. Oppositely imprinted genes H19 and insulin-like growth factor 2 are coexpressed in human androgenetic trophoblast. Am J Hum Genet. 1993;53(5):1096–102.PubMedPubMedCentral

35.

Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10(1):28–36.PubMedPubMedCentral

36.

Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE. 2007;2(9):e845.PubMedPubMedCentralCrossRef

37.

Yoshimizu T, Miroglio A, Ripoche M-A, Gabory A, Vernucci M, Riccio A, Colnot S, Godard C, Terris B, Jammes H, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A. 2008;105(34):12417–22.PubMedPubMedCentralCrossRef

38.

Zhang L, Yang F, Yuan J-h, Yuan S-x, Zhou W-p, Huo X-s, Xu D, Bi H-s, Wang F. Sun S-h: epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577–86.PubMedCrossRef

39.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef

40.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.PubMedPubMedCentralCrossRef

41.

Verhaegh GW, Verkleij L, Vermeulen SHHM, den Heijer M, Witjes JA, Kiemeney LA. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008;54(5):1118–26.PubMedCrossRef

42.

Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V, Hogdall C, et al. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet. 2009;18(12):2297–304.PubMedPubMedCentralCrossRef

43.

Quaye L, Tyrer J, Ramus SJ, Song H, Wozniak E, DiCioccio RA, McGuire V, Høgdall E, Høgdall C, Blaakaer J, et al. Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS ONE. 2009;4(6):e5983.PubMedPubMedCentralCrossRef

44.

Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in african-american and younger women. Carcinogenesis. 2010;31(8):1417–23.PubMedPubMedCentralCrossRef

45.

Butt S, Harlid S, Borgquist S, Ivarsson M, Landberg G, Dillner J, Carlson J, Manjer J. Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC Res Notes. 2012;5:414.PubMedPubMedCentralCrossRef

46.

Yang C, Tang R, Ma X, Wang Y, Luo D, Xu Z, Zhu Y, Yang L. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the chinese Han population. Oncotarget. 2015;6(17):15311–20.PubMedPubMedCentralCrossRef

47.

Li S, Hua Y, Jin J, Wang H, Du M, Zhu L, Chu H, Zhang Z, Wang M. Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a chinese population. Oncotarget. 2016;7(18):25470–7.PubMedPubMedCentralCrossRef

48.

Hua Q, Lv X, Gu X, Chen Y, Chu H, Du M, Gong W, Wang M, Zhang Z. Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a chinese population. Mutagenesis. 2016;31(5):531–8.PubMedCrossRef

49.

Xia Z, Yan R, Duan F, Song C, Wang P, Wang K. Genetic polymorphisms in long noncoding RNA H19 are Associated with susceptibility to breast Cancer in Chinese Population. Med (Baltim). 2016;95(7):e2771.CrossRef

50.

Jin T, Wu X, Yang H, Liu M, He Y, He X, Shi X, Wang F, Du S, Ma Y, et al. Association of the mir-17-5p variants with susceptibility to cervical cancer in a chinese population. Oncotarget. 2016;7(47):76647–55.PubMedPubMedCentralCrossRef

51.

Gong W-J, Peng J-B, Yin J-Y, Li X-P, Zheng W, Xiao L, Tan L-M, Xiao D, Chen Y-X, Li X, et al. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in chinese patients with lung cancer. Acta Pharmacol Sin. 2017;38(4):581–90.PubMedPubMedCentralCrossRef

52.

Guo QY, Wang H, Wang Y. LncRNA H19 polymorphisms associated with the risk of OSCC in chinese population. Eur Rev Med Pharmacol Sci. 2017;21(17):3770–4.PubMed

53.

Hassanzarei S, Hashemi M, Sattarifard H, Hashemi SM, Bahari G. Genetic polymorphisms in long noncoding RNA H19 are associated with breast cancer susceptibility in iranian population. Meta Gene. 2017;14:1–5.CrossRef

54.

He TD, Xu D, Sui T, Zhu JK, Wei ZX, Wang YM. Association between H19 polymorphisms and osteosarcoma risk. Eur Rev Med Pharmacol Sci. 2017;21(17):3775–80.PubMed

55.

Hu P, Qiao O, Wang J, Li J, Jin H, Li Z, Jin Y. rs1859168 A > C polymorphism regulates HOTTIP expression and reduces risk of pancreatic cancer in a chinese population. World J Surg Oncol. 2017;15(1):155.PubMedPubMedCentralCrossRef

56.

Lin Y, Fu F, Chen Y, Qiu W, Lin S, Yang P, Huang M, Wang C. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. Onco Targets Ther. 2017;10:4369–78.PubMedPubMedCentralCrossRef

57.

Li L, Guo G, Zhang H, Zhou B, Bai L, Chen H, Zhao Y, Yan Y. Association between H19 SNP rs217727 and lung cancer risk in a chinese population: a case control study. BMC Med Genet. 2018;19(1):136.PubMedPubMedCentralCrossRef

58.

Yang M-L, Huang Z, Wang Q, Chen H-H, Ma S-N, Wu R, Cai W-S. The association of polymorphisms in lncRNA-H19 with hepatocellular cancer risk and prognosis. Biosci Rep 2018, 38(5).

59.

Yin Z, Cui Z, Li H, Li J, Zhou B. Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China. BMC Cancer. 2018;18(1):893.PubMedPubMedCentralCrossRef

60.

Yuan Z, Yu Y, Zhang B, Miao L, Wang L, Zhao K, Ji Y, Wang R, Ma H, Chen N, et al. Genetic variants in lncRNA H19 are associated with the risk of oral squamous cell carcinoma in a chinese population. Oncotarget. 2018;9(35):23915–22.PubMedPubMedCentralCrossRef

61.

Cui P, Zhao Y, Chu X, He N, Zheng H, Han J, Song F, Chen K. SNP rs2071095 in LincRNA H19 is associated with breast cancer risk. Breast Cancer Res Treat. 2018;171(1):161–71.PubMedCrossRef

62.

Abdollahzadeh S, Ghorbian S. Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. J Clin Lab Anal. 2019;33(3):e22826.PubMedCrossRef

63.

Hu C, Yang T, Pan J, Zhang J, Yang J, He J, Zou Y. Associations between H19 polymorphisms and neuroblastoma risk in chinese children. Biosci Rep 2019, 39(4).

64.

Li Z, Niu Y. Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in chinese population. Minerva Urol Nefrol. 2019;71(2):161–7.PubMedCrossRef

65.

Safari MR, Mohammad Rezaei F, Dehghan A, Noroozi R, Taheri M, Ghafouri-Fard S. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in iranian population. Gene. 2019;701:121–4.PubMedCrossRef

66.

Wang G, Liu Q, Cui K, Ma A, Zhang H. Association between H19 polymorphisms and NSCLC risk in a Chinese Population. J BUON. 2019;24(3):913–7.PubMed

67.

Wu E-R, Chou Y-E, Liu Y-F, Hsueh K-C, Lee H-L, Yang S-F, Su S-C. Association of lncRNA H19 gene polymorphisms with the occurrence of Hepatocellular Carcinoma. Genes (Basel) 2019, 10(7).

68.

Wei M, Wang X, Luo B. Association between lncRNA H19 polymorphisms and susceptibility to gastric carcinoma and EBV-associated gastric carcinoma in han population in qingdao. Chin J Cancer Biotherapy. 2019;26(6):676–82.

69.

Huang M-C, Chou Y-H, Shen H-P, Ng S-C, Lee Y-C, Sun Y-H, Hsu C-F, Yang S-F, Wang P-H. The clinicopathological characteristic associations of long non-coding RNA gene H19 polymorphisms with uterine cervical cancer. J Cancer. 2019;10(25):6191–8.PubMedPubMedCentralCrossRef

70.

Yang P-J, Hsieh M-J, Hung T-W, Wang S-S, Chen S-C, Lee M-C, Yang S-F, Chou Y-E. Effects of Long Noncoding RNA H19 polymorphisms on Urothelial Cell Carcinoma Development. Int J Environ Res Public Health 2019, 16(8).

71.

Cao Q, Li P, Cao P, Qian J, Du M, Li L, Wang M, Qin C, Shao P, Zhang Z, et al. Genetic variant in long non-coding RNA H19 modulates its expression and predicts renal cell Carcinoma susceptibility and mortality. Front Oncol. 2020;10:785.PubMedPubMedCentralCrossRef

72.

Ghapanchi J, Ranjbar Z, Mokhtari MJ, Koohpeima F, Derakhshan M, Khademi B, Ghaderi H, Sheikhbahaei S, Aliabadi E. The LncRNA H19 rs217727 polymorphism is Associated with oral squamous cell Carcinoma Susceptibility in Iranian Population. Biomed Res Int. 2020;2020:1634252.PubMedPubMedCentralCrossRef

73.

Deng Y, Zhou L, Yao J, Liu Y, Zheng Y, Yang S, Wu Y, Li N, Xu P, Lyu L, et al. Associations of lncRNA H19 polymorphisms at MicroRNA binding Sites with Glioma susceptibility and prognosis. Mol Ther Nucleic Acids. 2020;20:86–96.PubMedPubMedCentralCrossRef

74.

Yu B, Chen J, Hou C, Zhang L, Jia J. LncRNA H19 gene rs2839698 polymorphism is associated with a decreased risk of colorectal cancer in a chinese Han population: a case-control study. J Clin Lab Anal. 2020;34(8):e23311.PubMedPubMedCentralCrossRef

75.

Zhang H-B, Zeng Y, Li T-L, Wang G. Correlation between polymorphisms in IGF2/H19 gene locus and epithelial ovarian cancer risk in chinese population. Genomics. 2020;112(3):2510–5.PubMedCrossRef

76.

Li W, Hua R-X, Wang M, Zhang D, Zhu J, Zhang S, Yang Y, Cheng J, Zhou H, Zhang J, et al. H19 gene polymorphisms and Wilms tumor risk in chinese children: a four-center case-control study. Mol Genet Genomic Med. 2021;9(2):e1584.PubMedPubMedCentralCrossRef

77.

Pei J-S, Chen C-C, Chang W-S, Wang Y-C, Chen J-C, Hsiau Y-C, Hsu P-C, Hsu Y-N, Tsai C-W. Bau D-T: significant Associations of lncRNA H19 genotypes with susceptibility to Childhood Leukemia in Taiwan. Pharmaceuticals (Basel) 2021, 14(3).

78.

Tan T, Li J, Wen Y, Zou Y, Yang J, Pan J, Hu C, Yao Y, Zhang J, Xin Y, et al. Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic chinese population. J Cell Mol Med. 2021;25(2):742–50.PubMedCrossRef

79.

Zhang J, Liu M, Liang Y, Zhang M, Huang Z. Correlation between lncRNA H19 rs2839698 polymorphism and susceptibility to NK / T cell lymphoma in chinese population. J BUON. 2021;26(2):587–91.PubMed

80.

Khalil EH, Shaker OG, Hasona NA. Impact of rs2107425 polymorphism and expression of lncH19 and miR-200a on the susceptibility of Colorectal Cancer. Indian J Clin Biochem 2022.

81.

Li W, Jiang X, Jin X, Yan W, Liu Y, Li D, Zhao Z. Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: a PRISMA-compliant meta-analysis and bioinformatics prediction. Med (Baltim). 2020;99(15):e19322.CrossRef

82.

Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, Spruyt N, Hondermarck H, Dugimont T, Curgy J-J, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol. 2008;28(22):6731–45.PubMedPubMedCentralCrossRef

83.

Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X, Wang L, Wang C. Down-regulation of mir-24-3p in colorectal cancer is associated with malignant behavior. Med Oncol. 2015;32(1):362.PubMedCrossRef

84.

Inoguchi S, Seki N, Chiyomaru T, Ishihara T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto Y, et al. Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett. 2014;588(17):3170–9.PubMedCrossRef

85.

Gao T, He B, Pan Y, Gu L, Chen L, Nie Z, Xu Y, Li R, Wang S. H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway. Clin Transl Oncol. 2014;16(4):410–7.PubMedCrossRef

86.

McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, Bartel DP. The biochemical basis of microRNA targeting efficacy. Science 2019, 366(6472).

87.

Chu M, Yuan W, Wu S, Wang Z, Mao L, Tian T, Lu Y, Zhu B, Yang Y, Wang B, et al. Quantitative assessment of polymorphisms in H19 lncRNA and cancer risk: a meta-analysis of 13,392 cases and 18,893 controls. Oncotarget. 2016;7(48):78631–9.PubMedPubMedCentralCrossRef

88.

Liu X, Zhao Y, Li Y, Zhang J. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects. Artif Cells Nanomed Biotechnol. 2020;48(1):15–27.PubMedCrossRef

89.

Novikova IV, Hennelly SP, Sanbonmatsu KY. Structural architecture of the human long non-coding RNA, steroid receptor RNA activator. Nucleic Acids Res. 2012;40(11):5034–51.PubMedPubMedCentralCrossRef

Title: Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis
Authors: Maoquan Yang
Mingwei Zhang
Qiong Wang
Xiaojing Guo
Peizhen Geng
Jinhua Gu
Wansheng Ji
Li Zhang
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11164-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma

Sex-specific aspects in patients with oropharyngeal squamous cell carcinoma: a bicentric cohort study

The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma

Development and validation a radiomics nomogram for predicting thymidylate synthase status in hepatocellular carcinoma based on Gd-DTPA contrast enhanced MRI

Assessments of dietary intake and polygenic risk score in associations with colorectal cancer risk: evidence from the UK Biobank

S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer